CLBS119 for Repair of COVID-19 Induced Pulmonary Damage
NCT ID: NCT04522817
Last Updated: 2024-10-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1
INTERVENTIONAL
2020-10-05
2021-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure
NCT04574869
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
NCT04390217
Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19
NCT04490486
Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection
NCT04526912
Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19
NCT06383819
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CLBS119 Active Treatment
Single administration of CLBS119
CLBS119
Peripheral blood derived autologous CD34+ cells
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CLBS119
Peripheral blood derived autologous CD34+ cells
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Receiving or received ventilatory support for COVID-19 pneumonia/ARDS
* Evidence for ongoing pulmonary involvement based on P/F ratio \<300
* Able to provide informed consent
Exclusion Criteria
* History of autoimmune disease
* Evidence of multiorgan failure
* Subject is pregnant or lactating at the time of signing the consent
* Participation in any other clinical trial of an experimental treatment for COVID-19
* History of sickle cell disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lisata Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Douglas W Losordo, MD
Role: STUDY_DIRECTOR
Chief Medical Officer, Caladrius Biosciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NYU Langone Health
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLBS119-P01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.